Hemolytic anemia due to glucophosphate isomerase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:712OMIM:613470D55.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hemolytic anemia due to glucosephosphate isomerase (GPI) deficiency, also known as glucose-6-phosphate isomerase deficiency or phosphoglucose isomerase (PGI) deficiency, is a rare inherited metabolic disorder affecting red blood cells. GPI is an enzyme in the glycolytic (Embden-Meyerhof) pathway, which is the primary energy-producing pathway in red blood cells. When this enzyme is deficient, red blood cells cannot generate adequate energy (ATP), leading to their premature destruction (hemolysis). GPI deficiency is considered the second most common cause of hereditary nonspherocytic hemolytic anemia among glycolytic enzyme defects, after pyruvate kinase deficiency. Clinical features typically present in the neonatal or infantile period and include chronic hemolytic anemia of variable severity, jaundice (including neonatal hyperbilirubinemia that may require exchange transfusion), splenomegaly, and reticulocytosis. Some patients may experience hemolytic crises triggered by infections or other stressors. In severe cases, hydrops fetalis has been reported. A subset of patients may also exhibit mild neuromuscular manifestations, as GPI also functions as a neurotrophic factor (neuroleukin) outside of red blood cells, though neurological involvement is not a consistent feature. Treatment is primarily supportive. Red blood cell transfusions may be required during severe anemia or hemolytic crises, and folic acid supplementation is commonly recommended to support increased red cell production. Splenectomy has been performed in some patients with severe disease and may reduce transfusion requirements and improve hemoglobin levels, though hemolysis is not completely eliminated. Iron overload from chronic hemolysis and/or transfusions may necessitate iron chelation therapy. There is currently no curative treatment, though management of complications can significantly improve quality of life.

Also known as:

Clinical phenotype terms— hover any for plain English:

Nonspherocytic hemolytic anemiaHP:0001930Decreased glucosephosphate isomerase levelHP:0003568Unconjugated hyperbilirubinemiaHP:0008282CholecystitisHP:0001082PoikilocytosisHP:0004447Pigment gallstonesHP:0011981
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Hemolytic anemia due to glucophosphate isomerase deficiency.

View clinical trials →

No actively recruiting trials found for Hemolytic anemia due to glucophosphate isomerase deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hemolytic anemia due to glucophosphate isomerase deficiency community →

No specialists are currently listed for Hemolytic anemia due to glucophosphate isomerase deficiency.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hemolytic anemia due to glucophosphate isomerase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hemolytic anemia due to glucophosphate isomerase deficiencyForum →

No community posts yet. Be the first to share your experience with Hemolytic anemia due to glucophosphate isomerase deficiency.

Start the conversation →

Latest news about Hemolytic anemia due to glucophosphate isomerase deficiency

No recent news articles for Hemolytic anemia due to glucophosphate isomerase deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hemolytic anemia due to glucophosphate isomerase deficiency

What is Hemolytic anemia due to glucophosphate isomerase deficiency?

Hemolytic anemia due to glucosephosphate isomerase (GPI) deficiency, also known as glucose-6-phosphate isomerase deficiency or phosphoglucose isomerase (PGI) deficiency, is a rare inherited metabolic disorder affecting red blood cells. GPI is an enzyme in the glycolytic (Embden-Meyerhof) pathway, which is the primary energy-producing pathway in red blood cells. When this enzyme is deficient, red blood cells cannot generate adequate energy (ATP), leading to their premature destruction (hemolysis). GPI deficiency is considered the second most common cause of hereditary nonspherocytic hemolytic a

How is Hemolytic anemia due to glucophosphate isomerase deficiency inherited?

Hemolytic anemia due to glucophosphate isomerase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hemolytic anemia due to glucophosphate isomerase deficiency typically begin?

Typical onset of Hemolytic anemia due to glucophosphate isomerase deficiency is neonatal. Age of onset can vary across affected individuals.